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The bombesin-litorin family of peptides is characterized by the common amino acid sequence -Gly-His-X- 
Met-NH, at the C-terminus, where X is a hydrophobic or aromatic residue. A new member of this family, 
rohdei-litorin, has been isolated from amphibian skin and its structure shown to be: Glp-Leu-Trp-Ala-Thr- 
Gly-His-Phe-Met-NH,. This new peptide displayed a greater affinity than other members of the family for 
rat urinary bladder receptors. A litorin-like peptide, with high affinity for this kind of receptor, has already 
been described in mammalian spinal cord and named neuromedin B. Rohdei-litorin shares with neuromedin 
B the entire C-terminal octrapeptide and may be considered the amphibian counterpart of this mammalian 
Rohdei-Iitorin 
1. INTRODUCTION 
Extracts of the skin of the South American hilyd 
neuropeptide. 
Amino acid sequencing Amphibian skin 
frogs belonging to the genus Phyllomedusa contain 
a number of active peptide families, including the 
litorin-ranatensin family with the C-terminal pen- 
tapeptide -Val-Gly-His-Phe-NH2, and the new 
phyllolitorin family with the C-terminal sequence 
-Val-Gly-Ser-Phe(Leu)-Met-NHz, in which a serine 
residue replaces the usual histidine residue [1,2]. 
This paper describes the isolation, structure 
elucidation and preliminary pharmacological 
studies of a new litorin from methanol extracts of 
Phyllomedusa rohdei skin, designated rohdei- 
litorin. 
2. MATERIALS AND METHODS 
2.1. Amphibian material 
2397 specimens of P. rohdei were collected dur- 
ing the period January-April 1966 near Rio de 
Janeiro. The skins were removed immediately after 
killing, spread out and dried. Soon after their ar- 
rival in the laboratory by air mail, the dried skins 
Neuromedin 
were extracted twice with a volume of 80% 
methanol 15-20-times their weight. The combined 
extracts were filtered and kept at 3-4’C. 
2.2 Bioassay 
The following test preperations were used in the 
bioassay of litorin-like activity: (a) isolated smooth 
muscle preparations: rat uterus and guinea-pig 
large intestine; (b) in situ preparations: rat urinary 
bladder, guinea-pig gall bladder. Methods have 
been described in detail in [3]. 
2.3. Isolation procedure 
The methanol extract corresponding to 30 g 
dried skin was concentrated to a small volume, 
washed with petroleum ether to remove fats, and 
then evaporated to dryness. The residue was 
dissolved in 10 ml distilled water plus 190 ml of 
99% ethanol and the solution loaded on a column 
of 170 g alkaline alumina (Merck, Darmstadt). The 
column was eluted first with 3 portions (200 ml 
each) of 95% ethanol and then with ethanol-water 
mixtures of descending concentrations of ethanol. 
All the litorin-like activity emerged in the 95% 
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ethanol eluate with a peak in the second fraction, 
Only penta- and tetra-tryptophyilins emerged 
together with the litorin-like peptide; the bulk of 
other peptides was eluted by lower concentrations 
of ethanol. Purification of the active alumina 
eluates (equivalent o 3 g tissue) was carried out by 
gel filtration on Sephadex G-25 superfine using 0.1 
M acetic acid as eluent (flow rate 3 ml/15 min). 
Final purification of the active fraction was 
achieved by reverse-phase high-performance liquid 
chromatography (HPLC) on an Aquapore RP-300 
column (46x250 mm, Brownlee Labs), using a 
Beckman model 332 instrument, under the condi- 
tions detailed in the legend to fig.lA. Column ef- 
fluent was monitored by measuring the absorbance 
both at 220 and 280 nm with a Beckman 165 
Spectrophotometer. 
2.4. Structural analysis 
Amino acid analyses were performed with an 
LKB 4400 amino acid analyzer, equipped with a 
Spectra-Physics System I Computing Integrator 
after hydrolysis of the peptide (0.5-l nmol) in 6 N 
HCI at 110°C for 24 h in vacua. N-terminal 
analyses were performed by the dansyl chloride 
method according to Gray [4]. Amino acid se- 
quences were determined by the dansyl-Edman 
technique as described by Hartley [.5]. DNS-Trp 
was identified after hydrolysis with 4 M 
methanesulphonic acid [6,7]. The C-terminal se- 
quence was analyzed by carboxypeptidase Y 
(Boehringer) digestion in 0.1 M ammonium acetate 
at 37°C for 1 h (3-5 fig enzyme/nmol peptide). 
Digestion with pyroglutamate aminopeptidase 
(Boehringer) was performed according to Schwabe 
and McDonald [8]. Methanolysis of the pyr- 
rolidone ring was performed by dissolving 20 nmol 
of the peptide in 100~1 of a freshly prepared solu- 
tion of methanob’acetyl chloride (95 : 8, v/v) and 
incubating for 24 h at room temperature. 35 nmol 
peptide was subdigested with ~-chymotrypsin 
(Worthington) at 38°C at an enzyme/substrate 
ratio = 1: 35. After 40 min the digest was directly 
injected onto the HPLC reverse-phase column and 
chromatographed under the conditions detailed in 
fig.lB. 
3. RESULTS AND DISCUSSION 
The active fraction from Sephadex G-25 was in- 
54 
jetted onto the reverse-phase column and eluted 
with a linear gradient of aqueous acetonitrile con- 
taining 0.2% trifluoroacetic acid as indicated in 
fig.lA. The amino acid composition of the active 
fraction from the reverse-phase column was deter- 
mined after acid hydrolysis to be: Thr (0.9) Glu 
(l.O), Gly (l.O), Ala (0.9), Met (l.l), Leu (l.O), 
Phe (1 .O), His (0.9) (mob’mol peptide). The 
presence of tryptophan was determined by spec- 
trophotometric analysis. The peptide was 
unresponsive to N-terminal analysis. After treat- 
ment with methanolic HCl it became amenable to 
dansyl-Edman degradation and the following par- 
tial sequence was established: Glx-Leu-Trp-Ala- 
Thr-Gly. Reaction with dansyl-chloride of an ali- 
quot of peptide which had been preincubated with 
pyroglutamate aminopeptidase yielded leucine as 
the N-terminal residue, thus indicating the 
presence of a pyroglutamic acid at the N-terminus 
of the original peptide. Carboxypeptidase Y diges- 
tion released Met (1 .O mollmol peptide), Phe (0.8), 
His (0.7). After chymotryptic digestion of an ali- 
quot of the peptide, 4 fragments were purified by 
reverse-phase HPLC (fig. 1B); their amino acid 
Fig.1. (A) Reverse-phase HPLC of the active fraction 
from Sephadex G-25. Flow rate: 1.2 mllmin. Column: 
Aquapore RP-300, 4.6 x 250 mm (Brownlee Labs). Sol- 
vent system: a 30 min linear gradient elution from 0.2% 
trifluoroacetjc acid (TFA) in water to 0.2% TFA in 70% 
acetonitrile. (-) Absorbance at 220 nm; (. s .) % of 
solvent B in the gradient elution. The active fraction is 
indicated by the vertical arrow. (B) Reverse-phase 
HPLC of the chymotryptic digest of the active peptide. 
Conditions as in (---): Absorbance at 280 nm. 
Volume 182, number 1 FEBS LETTERS March 1985 
Table 1 
Amino acid composition of the chymotryptic fragments 
Amino acid 
Thr 
Glu 
GlY 
Ala 
Met 
Leu 
Phe 
His 
Trp 
N-terminal 
residue 
Ch-1 
1.0 
0.9 
0.8” 
_c 
Ch-2 
0.9 
1.0 
1.0 
0.9 
1.0 
Ala 
Ch-3 
1.0 
Met 
Ch-4 
0.9 
1.0 
1.1 
0.9 
0.9 
1.0 
0.8 
+b 
_c 
aDetermined after hydrolysis with 4 M methanesulphon- 
ic acid [7] 
bThe presence of tryptophan was indicated by the absor- 
bance at 280 nm 
‘Unreactive with DNS-C 1 
compositions and results of N-terminal analysis 
are reported in table 1. An aliquot of fragment 
Ch-3 loaded on the amino acid analyzer without 
previous acid hydrolysis chromatographed in the 
position of authentic methionine amide. Fragment 
Ch-2, submitted to dansyl-Edman degradation, 
gave the sequence: Ala-Thr-Cly-His-Phe. 
From the results described above, the complete 
amino acid sequence of the peptide was determined 
to be: Glp-Leu-Trp-Ala-Thr-Gly-His-Phe-Met- 
NH2, as shown in fig.2. 
The relative potencies of litorin, phyllolitorin 
and rohdei-litorin are shown in table 2. Rohdei- 
litorin presents harp divergence of activity in com- 
parison to litorin. It is twice as potent as litorin on 
the rat urinary bladder and 4-5 and lo-12-times 
less potent on the guinea-pig large intestine and 
L-L 
GLP-LEU-TRP-ALA-THR-GLY-HIS-PHE-MET-NH2 
---dd- 
i-- CH-l--4 - h-2 - b CH-3 -I 
-AA-r_) 
c------- CH-4 ____I 
Fig.2. Complete amino acid sequence of the active pep- 
tide. (-). By dansyl-Edman degradation. (-) By car- 
boxypeptidase Y digestion. CH, chymotryptic peptides. 
guinea-pig gall bladder, respectively. On the other 
hand, in all bioassays used, rohdei-litorin was 
more potent than phyllolitorin. 
The structure of this new nonapeptide is com- 
pared with that of other litorin-like peptides in 
fig.3. Rohdei-litorin shows in its sequence amino 
acid substitutions recalling on the one hand 
ranatensins C and R from Japanese frogs, and on 
the other the phyllolitorins from the Brazilian frog 
P. sauvagei. Thus, leucine at position 8 from the 
C-terminus is peculiar to all the litorin-like pep- 
tides so far isolated from Phyllomedusa skin, be- 
ing also present in neuromedin B whereas 
threonine at position 5 from the C-terminus is 
common to rohdein-litorin, to ranatensins C and R 
and again to neuromedin B. Thus neuromedin B 
may be properly considered as the mammalian 
counterpart of the amphibian litorin-ranatensin 
peptide family. In fact, it shares with ranatensins 
C and R the entire C-terminal heptapeptide and 
with rohdei-litorin the entire C-terminal octapep- 
tide. On the basis of results obtained in parallel 
bioassays it seems highly probable that the spec- 
trum of biological activity of rohdei-litorin is very 
similar to that of neuromedin B. Synthetic 
analogues of rohdei-litorin will help to clarify the 
relative importance of the leucine and threonine 
Table 2 
Parallel bioassays of litorin-like peptides 
Litorin Rohdei-litorin Phyllolitorin 
Rat uterus 100 40-120 3-15 
Guinea-pig large intestine 100 20-25 1.5-3 
Guinea-pig gall bladder (in situ) 100 8-10 2-4 
Rat urinary blader (in situ) 100 200-230 loo-120 
The potency of litorin has been considered to be arbitrarily 100. Relative potencies are calculated 
on the basis of threshold doses 
55 
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AMPHIBIAN: 
HYLA Glp-Gln-Trp-Ala-Val-Gly-His-Phe-~~et-NH* LITORIN 
alp-Leu-Trp-Ala-Val-Gly-per-Phe-~~et-NH~ PHYLlOLITORI~~ 
Glp-Leu-Trp-Ala-Val-Gly-Ser-Leu-Met-NH2 LEU'-PHYLLOLITORIN 
Glp-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 ROHDEI-LITORIN 
RANA 
MAMMALS: _- 
-Pro-Gln-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 C-TERMINAL NONAPEPTIDE 
OF RANATENSIN C 
Fig.3. Amino acid sequences of litorin-like peptides. 
residues in determinist the sharp quantitative dif- 
ferences in peripheral activity observed between 
rohdei-litorin and litorin. 
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